HeartFlow, Inc. (HTFL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HeartFlow, Inc. (HTFL) trades at $27.11 with AI Score 28/100 (Grade F). HeartFlow, Inc. provides non-invasive diagnostic solutions for coronary artery disease, leveraging AI and computational fluid dynamics. Market cap: $2.34B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026HTFL stock analysis for 2026: Analysts have set a consensus price target of $38.00 for HeartFlow, Inc., suggesting 40.2% upside from the current price of $27.11. The AI MoonshotScore is 28/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
HTFL: 3/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →HeartFlow, Inc. (HTFL) Healthcare & Pipeline Overview
HeartFlow, Inc. specializes in non-invasive diagnostic solutions for coronary artery disease, utilizing its AI-powered HeartFlow Platform to create personalized 3D heart models. This technology enhances diagnostic accuracy and treatment planning, positioning HeartFlow as a key innovator in the healthcare information services sector.
What Is the Investment Thesis for HTFL?
HeartFlow, Inc. presents a notable research candidate within the healthcare technology sector, driven by its innovative HeartFlow Platform. The platform's ability to provide detailed, non-invasive assessments of coronary artery disease offers significant value to healthcare providers and patients. Key value drivers include the increasing adoption of the HeartFlow Platform by hospitals and cardiology practices, expansion into new geographic markets, and ongoing advancements in AI and computational fluid dynamics. The company's gross margin of 76.8% indicates strong profitability potential as adoption scales. Potential catalysts include positive clinical trial results and favorable regulatory decisions. However, investors should be aware of risks such as competition from established medical device companies and the need for continuous innovation to maintain a competitive edge.
Based on FMP financials and quantitative analysis
HTFL Key Highlights
- Market capitalization of $2.34B reflects investor confidence in HeartFlow's growth potential.
- Gross margin of 76.8% demonstrates strong profitability and efficient cost management.
- The HeartFlow Platform utilizes AI and computational fluid dynamics to create personalized 3D models of the heart, offering a unique and advanced diagnostic tool.
- The company's non-invasive approach reduces the need for more invasive procedures, potentially lowering healthcare costs and improving patient outcomes.
- Operating in the Healthcare Information Services industry, HeartFlow is positioned to benefit from the increasing demand for advanced diagnostic technologies.
Who Are HTFL's Competitors?
HTFL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LEGN Legend Biotech Corporation | $27.97 | -6.49% | $5.17B | 32 |
| PRVA Privia Health Group, Inc. | $27.27 | -0.35% | $3.44B | 89 |
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.72 | +3.54% | $8.46M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HTFL's Key Strengths?
- Innovative HeartFlow Platform with AI and computational fluid dynamics.
- Non-invasive diagnostic solution reduces the need for invasive procedures.
- Strong gross margin of 76.8%.
- Established market presence in the non-invasive cardiac imaging space.
What Are HTFL's Weaknesses?
- Negative profit margin of -66.3%.
- Reliance on a single product platform.
- Requires continuous innovation to maintain a competitive edge.
- Potential for reimbursement challenges from healthcare payers.
What Could Drive HTFL Stock Higher?
- Publication of new clinical trial results demonstrating the clinical and economic benefits of the HeartFlow Platform.
- Increasing adoption of the HeartFlow Platform by hospitals and cardiology practices.
- Expansion into new geographic markets, particularly in Europe and Asia.
- Development of new applications for the HeartFlow Platform beyond coronary artery disease.
What Are the Key Risks for HTFL?
- Competition from established medical device companies with greater resources and market share.
- Technological obsolescence as new diagnostic technologies emerge.
- Regulatory changes and compliance requirements that could increase operating costs.
- Economic downturns and healthcare budget constraints that could reduce demand for the HeartFlow Platform.
What Are the Growth Opportunities for HTFL?
- Expansion into New Geographic Markets: HeartFlow has the opportunity to expand its market presence globally, particularly in regions with high prevalence of coronary artery disease and increasing healthcare expenditure. Entering new markets requires strategic partnerships with local healthcare providers and regulatory approvals. The global market for cardiovascular diagnostic devices is projected to reach $25 billion by 2028, offering substantial growth potential for HeartFlow.
- Development of New Applications for the HeartFlow Platform: HeartFlow can leverage its AI and computational fluid dynamics expertise to develop new applications for its platform beyond coronary artery disease. This includes exploring diagnostic solutions for other cardiovascular conditions, such as heart failure and valvular heart disease. Expanding the platform's capabilities will broaden its market reach and increase its value proposition to healthcare providers.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with leading hospitals and cardiology practices can accelerate the adoption of the HeartFlow Platform. These partnerships can involve integrating the platform into existing clinical workflows, conducting joint research studies, and co-marketing the technology to referring physicians. Collaborations with key opinion leaders in cardiology can also enhance HeartFlow's credibility and market visibility.
- Advancements in AI and Computational Fluid Dynamics: Continued investment in AI and computational fluid dynamics can further enhance the accuracy and efficiency of the HeartFlow Platform. This includes developing more sophisticated algorithms for analyzing blood flow dynamics and improving the visualization of 3D heart models. These advancements will strengthen HeartFlow's competitive advantage and attract new customers.
- Focus on Value-Based Healthcare: As healthcare systems increasingly shift towards value-based care models, HeartFlow is well-positioned to demonstrate the economic benefits of its technology. By reducing the need for invasive procedures and improving patient outcomes, the HeartFlow Platform can help healthcare providers lower costs and improve the quality of care. Emphasizing the value proposition of the platform can drive adoption and market share growth.
What Opportunities Does HTFL Have?
- Expansion into new geographic markets.
- Development of new applications for the HeartFlow Platform.
- Strategic partnerships with healthcare providers.
- Increasing adoption of value-based healthcare models.
What Threats Does HTFL Face?
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes and compliance requirements.
- Economic downturns and healthcare budget constraints.
What Are HTFL's Competitive Advantages?
- Proprietary AI and computational fluid dynamics technology that is difficult to replicate.
- Extensive clinical validation of the HeartFlow Platform, demonstrating its accuracy and effectiveness.
- Strong relationships with key opinion leaders in cardiology.
- Established market presence and brand recognition in the non-invasive cardiac imaging space.
What Does HTFL Do?
Founded in 2007 and headquartered in Mountain View, California, HeartFlow, Inc. is a medical technology company focused on revolutionizing the diagnosis and management of coronary artery disease. The company's core innovation is the HeartFlow Platform, which employs artificial intelligence and computational fluid dynamics to generate a personalized, three-dimensional model of a patient's heart. This model is derived from standard coronary computed tomography angiography (CTA) scans, providing clinicians with detailed insights into blood flow, stenosis (narrowing of arteries), and the composition of plaque. HeartFlow's technology overcomes the limitations of traditional non-invasive imaging tests, offering a more precise and comprehensive assessment of coronary artery health. By providing detailed information about blood flow dynamics, HeartFlow enables physicians to make more informed decisions regarding patient treatment, potentially reducing the need for invasive procedures. HeartFlow's solutions are used by healthcare providers worldwide, marking its significant global presence. The company continues to innovate in the field of cardiovascular diagnostics, aiming to improve patient outcomes and reduce healthcare costs associated with coronary artery disease.
What Products and Services Does HTFL Offer?
- Develops and markets the HeartFlow Platform, a non-invasive diagnostic tool for coronary artery disease.
- Utilizes AI and computational fluid dynamics to create personalized 3D models of a patient's heart.
- Provides detailed insights into blood flow, stenosis, and plaque composition.
- Offers a more precise and comprehensive assessment of coronary artery health compared to traditional non-invasive imaging tests.
- Helps physicians make more informed decisions regarding patient treatment.
- Reduces the need for invasive procedures, potentially lowering healthcare costs and improving patient outcomes.
How Does HTFL Make Money?
- Generates revenue through the sale of the HeartFlow Platform to hospitals and cardiology practices.
- Offers subscription-based access to the platform, providing ongoing software updates and support.
- Charges fees per patient scan analyzed using the HeartFlow Platform.
- May generate revenue through strategic partnerships with healthcare providers and research institutions.
What Industry Does HTFL Operate In?
HeartFlow operates within the rapidly evolving healthcare information services industry, which is experiencing significant growth due to increasing demand for advanced diagnostic technologies and personalized medicine. The market for non-invasive cardiac imaging is expanding, driven by the need for more accurate and cost-effective diagnostic solutions. HeartFlow's competitive landscape includes established medical device companies and emerging technology firms. The company's AI-powered HeartFlow Platform differentiates it from competitors by providing detailed insights into blood flow dynamics and plaque composition, enhancing diagnostic accuracy and treatment planning.
Who Are HTFL's Key Customers?
- Hospitals and cardiology practices seeking to improve the accuracy and efficiency of coronary artery disease diagnosis.
- Cardiologists and other healthcare professionals who use the HeartFlow Platform to guide treatment decisions.
- Patients with suspected or known coronary artery disease who undergo HeartFlow analysis as part of their diagnostic workup.
- Research institutions and pharmaceutical companies conducting clinical trials related to cardiovascular disease.
Company Profile
HeartFlow, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Mountain View, US. The company is led by CEO John Farquhar. HTFL has traded publicly since 2025.
F-Score 5/9Financial Health
HeartFlow, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 20.47 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on assets is -32.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.
HTFL Valuation & Market Position
With a $2.34B market cap, HeartFlow, Inc. sits in the mid-cap segment of the market. Relative to its peer group, HTFL's quantitative score of 28/100 is below the peer average of 65/100.
FY2026 estForward Outlook
Wall Street analysts project HeartFlow, Inc. revenue of about $229.9M for fiscal 2026, with EPS near $-0.49. The estimate reflects 6 contributing analysts.
HTFL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative HeartFlow Platform with AI and computational fluid dynamics.
- Non-invasive diagnostic solution reduces the need for invasive procedures.
- Strong gross margin of 76.8%.
- Established market presence in the non-invasive cardiac imaging space.
Bear Case
- Negative profit margin of -66.3%.
- Reliance on a single product platform.
- Requires continuous innovation to maintain a competitive edge.
- Potential for reimbursement challenges from healthcare payers.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
HTFL Latest News
-
Earnings Scheduled For May 14, 2026
benzinga · May 14, 2026
-
Earnings Volatility Watch: 10 Stocks With More Than 17% Implied Moves This Week
benzinga · May 10, 2026
HTFL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HTFL.
Price Targets
Consensus target: $38.00
HTFL MoonshotScore
What does this score mean?
The MoonshotScore rates HTFL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Farquhar
CEO
John Farquhar is the Chief Executive Officer of HeartFlow, Inc., leading a team of 626 employees. His background includes extensive experience in the medical technology industry, with a focus on commercializing innovative diagnostic and therapeutic solutions. Prior to joining HeartFlow, he held leadership positions at various medical device companies, where he was responsible for driving revenue growth, expanding market share, and developing strategic partnerships. He holds an MBA from a top-tier business school and a bachelor's degree in engineering.
Track Record: Under John Farquhar's leadership, HeartFlow has experienced significant growth in revenue and market adoption of the HeartFlow Platform. He has overseen the expansion of the company's commercial operations, the development of new applications for the platform, and the strengthening of relationships with key opinion leaders in cardiology. His strategic decisions have positioned HeartFlow as a leading innovator in the non-invasive cardiac imaging space.
HTFL Healthcare Stock FAQ
What does Heartflow, Inc. Common Stock do?
HeartFlow, Inc. is a medical technology company specializing in non-invasive diagnostic solutions for coronary artery disease. Its core product, the HeartFlow Platform, uses artificial intelligence and computational fluid dynamics to create personalized 3D models of a patient's heart from standard coronary computed tomography angiography (CTA) scans. This platform provides detailed insights into blood flow, stenosis, and plaque composition, enabling physicians to make more informed treatment decisions and potentially reduce the need for invasive procedures. HeartFlow's technology aims to improve patient outcomes and lower healthcare costs associated with coronary artery disease.
What do analysts say about HTFL stock?
Analyst coverage of HeartFlow, Inc. Common Stock (HTFL) focuses on the company's growth potential within the healthcare technology sector. Key valuation metrics include market capitalization and gross margin. Analysts highlight the increasing adoption of the HeartFlow Platform, expansion into new geographic markets, and ongoing advancements in AI and computational fluid dynamics as key growth drivers. Investor sentiment is influenced by clinical trial results, regulatory approvals, and competitive dynamics within the non-invasive cardiac imaging space. However, no specific buy/sell recommendations are provided.
What are the main risks for HTFL?
HeartFlow, Inc. faces several risks, including competition from established medical device companies with greater resources, the potential for technological obsolescence as new diagnostic technologies emerge, and regulatory changes that could increase operating costs. Additionally, economic downturns and healthcare budget constraints could reduce demand for the HeartFlow Platform. The company's reliance on a single product platform also poses a risk, as does the potential for reimbursement challenges from healthcare payers. Managing these risks is crucial for HeartFlow's long-term success.
What are the key factors to evaluate for HTFL?
HeartFlow, Inc. (HTFL) holds an AI score of 28/100 (low). Analysts target $38.00 (+40%). Not financial advice.
How frequently does HTFL data refresh on this page?
HTFL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HTFL's recent stock price performance?
HeartFlow, Inc. (HTFL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative HeartFlow Platform with AI and computational fluid dynamics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HTFL overvalued or undervalued right now?
Valuing HeartFlow, Inc. (HTFL) requires multiple metrics. Analysts target $38.00 (+40%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HTFL?
Before investing in HeartFlow, Inc. (HTFL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided source data and may not reflect the most current developments.
- Financial data is as of the last reported period.